In response to Roniciclib, the expression of the cell surface stemness antigens CD44v6, CD114, NCL and GPC2 is inhibited in both cell lines and neurospheres, showing a more pronounced reaction to treatment especially for NB CSCs. Here, GPC2 is linked to neuroblastoma.